Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628871 · ClinicalTrials.gov registry record
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
A clinical trial of Hemophilia B and Mucopolysaccharidosis II, sponsored by Sangamo Therapeutics.
- Active
- Registry status
- 13
- Enrollment target
- 5
- Study locations
NCT04628871: Active study of Hemophilia B and Mucopolysaccharidosis II, sponsored by Sangamo Therapeutics.
NCT04628871 is a study of Hemophilia B and Mucopolysaccharidosis II that is active but no longer recruiting, run by Sangamo Therapeutics. The registered enrollment target is 13 participants, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04628871, a study of Hemophilia B and Mucopolysaccharidosis II, is active but no longer recruiting, sponsored by Sangamo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
Primary Outcome
Long-term safety of SB-318, SB-913, and SB-FIX by assessment of any newly-diagnosed or worsening of existing medical conditions.
Conditions Studied
Interventions
- BIOLOGICAL SB-318
- BIOLOGICAL SB-913
- BIOLOGICAL SB-FIX
Study Locations (5)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
New York
- New York University Grossman School of Medicine - New York
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2030-01-01 |
What the registry record for NCT04628871 still lists
NCT04628871 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Hemophilia B appearing as the primary indexed condition, and to 3 interventions - of which SB-318 is the first listed.
NCT04628871 lists 5 locations in 5 states (California, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT04628871 about?
NCT04628871 is a clinical study titled "Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX". Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
What is the current status of trial NCT04628871?
This trial is currently active not recruiting. The enrollment target is 13 participants. The study started on 2020-11-03. Estimated completion is 2030-01-01.
What conditions does trial NCT04628871 study?
This clinical trial studies the following conditions: Hemophilia B, Mucopolysaccharidosis II, Mucopolysaccharidosis I.
What interventions are being tested in trial NCT04628871?
The interventions under investigation include: SB-318 (BIOLOGICAL), SB-913 (BIOLOGICAL), SB-FIX (BIOLOGICAL).
Who is sponsoring clinical trial NCT04628871?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04628871 being conducted?
This trial has 5 study locations across California, Illinois, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04628871's enrollment target sits among peer trials
13 19th of 20 higher than 2 of 20 other Hemophilia B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI